---
title: "Why this top-ranked IBD 50 stock just tumbled on its earnings"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295139244.md"
description: "Exelixis stock toppled Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations."
datetime: "2026-08-06T20:21:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295139244.md)
  - [en](https://longbridge.com/en/news/295139244.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295139244.md)
generator: "portal-rs"
---

# Why this top-ranked IBD 50 stock just tumbled on its earnings

Exelixis stock toppled Thursday on a mixed second-quarter report, as sales of its bread-and-butter cancer drug lagged expectations.

### Related Stocks

- [EXEL.US](https://longbridge.com/en/quote/EXEL.US.md)

## Related News & Research

- [Exelixis Stock Slips as FDA Delays Cancer Drug Review, Analyst Weighs In](https://longbridge.com/en/news/298761132.md)
- [Exelixis Eyes CABOMETYX Growth, Zanzalintinib Catalysts Across Cancer Franchises](https://longbridge.com/en/news/298884991.md)
- [Exelixis Rated Hold as Zanzalintinib CRC Outlook Remains Mixed; $54 Price Target Reaffirmed](https://longbridge.com/en/news/298937347.md)
- [Exelixis Eyes Zanza Launch as CABOMETYX Growth Faces NET Ramp Hurdle](https://longbridge.com/en/news/299039523.md)
- [Vivesto’s Paccal Vet Shows Survival Benefit in Canine Hemangiosarcoma Study](https://longbridge.com/en/news/299046816.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**